Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 13Ovarian Neoplasms 2Breast Cancer Metastatic 2Uterine Cervical Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer 1Stomach Neoplasms 1Neoplasms 1HR+/HER2-breast Cancer 1HER2-negative Breast Cancer Brain Metastases 1Fludzoparib" and Anti-angiogenic 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Organoids 1Advanced Triple-Negative Breast Cancer 1Advanced Triple Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

lenvatinib 1camrelizumab 1apatinib 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1ALT-803 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple Negative Breast Cancer × apatinib × Breast × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡